Immuneering (NASDAQ:IMRX - Get Free Report)'s stock had its "buy" rating reiterated by analysts at Chardan Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $13.00 price objective on the stock.
IMRX has been the subject of several other reports. Oppenheimer lowered their price objective on Immuneering from $25.00 to $21.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Needham & Company LLC restated a "buy" rating and issued a $9.00 target price on shares of Immuneering in a research note on Wednesday.
Check Out Our Latest Stock Report on Immuneering
Immuneering Stock Performance
NASDAQ:IMRX opened at $1.82 on Wednesday. The stock has a market capitalization of $65.50 million, a PE ratio of -0.93 and a beta of 0.01. The company has a fifty day moving average of $1.53 and a two-hundred day moving average of $1.74. Immuneering has a fifty-two week low of $1.00 and a fifty-two week high of $3.83.
Immuneering (NASDAQ:IMRX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.01). Research analysts forecast that Immuneering will post -1.86 earnings per share for the current year.
Institutional Investors Weigh In On Immuneering
A number of large investors have recently modified their holdings of IMRX. Tang Capital Management LLC acquired a new position in Immuneering in the fourth quarter worth about $27,000. Jane Street Group LLC bought a new stake in shares of Immuneering in the 1st quarter worth $32,000. Marshall Wace LLP acquired a new position in Immuneering in the fourth quarter worth approximately $47,000. First Manhattan CO. LLC. acquired a new stake in Immuneering during the 4th quarter worth about $71,000. Finally, XTX Topco Ltd boosted its position in shares of Immuneering by 177.2% in the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock worth $72,000 after buying an additional 20,871 shares during the period. Institutional investors and hedge funds own 67.65% of the company's stock.
About Immuneering
(
Get Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
